RxDoctor Payments Data

Christine Basile, APRN

Psychiatric/Mental Health · Plymouth, MANPI 1447629647

Payments from drug & device makers

$1,341in general payments, 2019–2025

Across 76 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$436
  • Lundbeck LLC$246
  • Teva Pharmaceuticals USA, Inc.$179
  • Johnson & Johnson$140
  • Alkermes, Inc.$118
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$106
  • plus $116 from 7 others

What the payments were for

  • Food & beverage$1,29497%
  • Education$473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,341 in reported general payments places this provider in the 80th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$50,984
Medicare patients
71
Services billed
563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl145$229,041
Austedo XrDeutetrabenazine11$175,850
IngrezzaValbenazine Tosylate13$106,506
Invega SustennaPaliperidone Palmitate25$90,185
TrintellixVortioxetine Hydrobromide13$20,104
VyvanseLisdexamfetamine Dimesylate44$17,978
Aripiprazole53$6,159
Olanzapine151$5,216
Ramelteon42$4,733
Buspirone Hcl138$3,276
Methylphenidate ErMethylphenidate Hcl57$3,110
Bupropion XlBupropion Hcl84$2,330
Quetiapine Fumarate79$2,139
Fluoxetine Hcl86$2,082
Trazodone Hcl108$2,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$436$229,041145 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$179$175,85011 claims
Neurocrine Biosciences, Inc.Ingrezza$15$106,50613 claims
Johnson & JohnsonInvega Sustenna$140$90,18525 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$13$38,08157 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Plymouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →